Vaccinex (VCNX) Competitors $1.00 +0.48 (+93.95%) As of 02:55 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VCNX vs. ALZN, ARTL, BCLI, MYNZ, INAB, ACXP, APLM, SBFM, AEZS, and CDIOShould you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include Alzamend Neuro (ALZN), Artelo Biosciences (ARTL), Brainstorm Cell Therapeutics (BCLI), Mainz Biomed (MYNZ), IN8bio (INAB), Acurx Pharmaceuticals (ACXP), Apollomics (APLM), Sunshine Biopharma (SBFM), Aeterna Zentaris (AEZS), and Cardio Diagnostics (CDIO). These companies are all part of the "pharmaceutical products" industry. Vaccinex vs. Its Competitors Alzamend Neuro Artelo Biosciences Brainstorm Cell Therapeutics Mainz Biomed IN8bio Acurx Pharmaceuticals Apollomics Sunshine Biopharma Aeterna Zentaris Cardio Diagnostics Vaccinex (NASDAQ:VCNX) and Alzamend Neuro (NASDAQ:ALZN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends. Do analysts rate VCNX or ALZN? Alzamend Neuro has a consensus price target of $45.00, suggesting a potential upside of 1,707.23%. Given Alzamend Neuro's stronger consensus rating and higher possible upside, analysts clearly believe Alzamend Neuro is more favorable than Vaccinex.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor VCNX or ALZN? In the previous week, Alzamend Neuro had 3 more articles in the media than Vaccinex. MarketBeat recorded 3 mentions for Alzamend Neuro and 0 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 beat Alzamend Neuro's score of -0.12 indicating that Vaccinex is being referred to more favorably in the media. Company Overall Sentiment Vaccinex Neutral Alzamend Neuro Neutral Do institutionals and insiders hold more shares of VCNX or ALZN? 50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 49.6% of Alzamend Neuro shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Comparatively, 30.2% of Alzamend Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is VCNX or ALZN more profitable? Vaccinex's return on equity of 0.00% beat Alzamend Neuro's return on equity.Company Net Margins Return on Equity Return on Assets VaccinexN/A N/A -383.58% Alzamend Neuro N/A -181.34%-116.84% Which has higher earnings and valuation, VCNX or ALZN? Alzamend Neuro has lower revenue, but higher earnings than Vaccinex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaccinex$388K6.70-$20.25M-$48.27-0.02Alzamend NeuroN/AN/A-$4.51MN/AN/A Which has more risk and volatility, VCNX or ALZN? Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500. Comparatively, Alzamend Neuro has a beta of -0.32, suggesting that its stock price is 132% less volatile than the S&P 500. SummaryVaccinex and Alzamend Neuro tied by winning 6 of the 12 factors compared between the two stocks. Get Vaccinex News Delivered to You Automatically Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VCNX vs. The Competition Export to ExcelMetricVaccinexPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.60M$834.68M$5.82B$9.73BDividend YieldN/A4.84%3.84%4.09%P/E Ratio-0.021.1731.1525.97Price / Sales6.7026.53476.16171.70Price / CashN/A19.5637.1558.38Price / Book-0.396.639.116.39Net Income-$20.25M-$4.94M$3.26B$265.66M7 Day Performance27.70%0.95%2.11%1.98%1 Month Performance-4.67%2.99%5.12%1.33%1 Year Performance-80.51%11.85%31.25%21.15% Vaccinex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VCNXVaccinex0.5271 of 5 stars$1.00+93.9%N/A-90.1%$2.60M$388K-0.0240ALZNAlzamend Neuro2.6108 of 5 stars$2.42+0.8%$180.00+7,338.0%-94.0%$7.02MN/A0.004Analyst ForecastARTLArtelo Biosciences3.1905 of 5 stars$9.76-2.7%$24.00+146.0%+18.5%$6.83MN/A-0.545BCLIBrainstorm Cell Therapeutics2.3805 of 5 stars$0.62+2.3%N/A-88.4%$6.79MN/A-0.1840Short Interest ↓MYNZMainz Biomed2.3513 of 5 stars$1.48-0.7%$14.00+845.9%-87.6%$6.78M$890K-0.0230Short Interest ↑Gap UpINABIN8bio3.9142 of 5 stars$2.23-1.8%$180.00+7,971.7%-86.2%$6.78MN/A-0.2520Short Interest ↓ACXPAcurx Pharmaceuticals3.1011 of 5 stars$4.19-6.6%$31.00+640.7%-90.2%$6.45MN/A-0.303APLMApollomics0.0602 of 5 stars$5.87+3.1%N/A-53.8%$6.45M$1.49M0.0045Positive NewsGap UpSBFMSunshine Biopharma2.2075 of 5 stars$1.42-1.0%$15.00+960.1%-52.6%$6.45M$34.87M-0.013AEZSAeterna ZentarisN/A$3.58-0.4%N/A-52.6%$6.42M$2.37M-0.2420CDIOCardio Diagnostics2.7056 of 5 stars$3.67+5.5%$60.00+1,534.9%-72.4%$6.39M$40K0.001Short Interest ↑ Related Companies and Tools Related Companies ALZN Competitors ARTL Competitors BCLI Competitors MYNZ Competitors INAB Competitors ACXP Competitors APLM Competitors SBFM Competitors AEZS Competitors CDIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VCNX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access